41 related articles for article (PubMed ID: 10803931)
1. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease.
Bohlen H; Kessler M; Sextro M; Diehl V; Tesch H
Ann Hematol; 2000 Mar; 79(3):110-3. PubMed ID: 10803931
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles.
Badila E; Japie C; Vrabie AM; Badila A; Georgescu A
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830690
[TBL] [Abstract][Full Text] [Related]
3. MHCII Expression on Peripheral Blood Monocytes in Canine Lymphoma: An Impact of Glucocorticoids.
Rzepecka A; Jagielski D; Cywińska A; Sapierzyński R; Żmigrodzka M; Witkowska-Piłaszewicz O; Winnicka A
Animals (Basel); 2022 Aug; 12(16):. PubMed ID: 36009726
[TBL] [Abstract][Full Text] [Related]
4. Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies.
Xie Y; Yang H; Yang C; He L; Zhang X; Peng L; Zhu H; Gao L
Front Oncol; 2022; 12():933666. PubMed ID: 35875135
[TBL] [Abstract][Full Text] [Related]
5. SNPs in genes encoding for IL-10, TNF-α, and NFκB p105/p50 are associated with clinical prognostic factors for patients with Hodgkin lymphoma.
Gaiolla RD; Moraes MPT; de Oliveira DE
PLoS One; 2021; 16(3):e0248259. PubMed ID: 33684151
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
Hsi ED; Li H; Nixon AB; Schöder H; Bartlett NL; LeBlanc M; Smith S; Kahl BS; Leonard JP; Evens AM; Scott DW; Rimsza LM; Friedberg JW
Blood; 2019 Apr; 133(16):1762-1765. PubMed ID: 30723079
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10.
Llopiz D; Ruiz M; Silva L; Sarobe P
Front Immunol; 2018; 9():1923. PubMed ID: 30233565
[TBL] [Abstract][Full Text] [Related]
8.
Vera-Lozada G; Minnicelli C; Segges P; Stefanoff G; Kristcevic F; Ezpeleta J; Tapia E; Niedobitek G; Barros MHM; Hassan R
Oncoimmunology; 2018; 7(5):e1389821. PubMed ID: 29721365
[TBL] [Abstract][Full Text] [Related]
9. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
[No Abstract] [Full Text] [Related]
10. Circulating interleukin-10 levels and human papilloma virus and Epstein-Barr virus-associated cancers: evidence from a Mendelian randomization meta-analysis based on 11,170 subjects.
Qu K; Pang Q; Lin T; Zhang L; Gu M; Niu W; Liu C; Zhang M
Onco Targets Ther; 2016; 9():1251-67. PubMed ID: 27022283
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.
Negi AK; Renuka ; Bhatnagar A; Agnihotri N
Inflammopharmacology; 2016 Feb; 24(1):11-22. PubMed ID: 26749133
[TBL] [Abstract][Full Text] [Related]
12. Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis.
Zhao S; Wu D; Wu P; Wang Z; Huang J
PLoS One; 2015; 10(10):e0139598. PubMed ID: 26440936
[TBL] [Abstract][Full Text] [Related]
13. Short telomere length in peripheral blood leukocyte predicts poor prognosis and indicates an immunosuppressive phenotype in gastric cancer patients.
Qu F; Li R; He X; Li Q; Xie S; Gong L; Ji G; Lu J; Bao G
Mol Oncol; 2015 Mar; 9(3):727-39. PubMed ID: 25515040
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in hodgkin lymphoma.
Cuccaro A; Bartolomei F; Cupelli E; Galli E; Giachelia M; Hohaus S
Mediterr J Hematol Infect Dis; 2014; 6(1):e2014053. PubMed ID: 25045461
[TBL] [Abstract][Full Text] [Related]
15. Regulation of adaptive immunity; the role of interleukin-10.
Ng TH; Britton GJ; Hill EV; Verhagen J; Burton BR; Wraith DC
Front Immunol; 2013; 4():129. PubMed ID: 23755052
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma.
Schoof N; Franklin J; Fürst R; Zander T; von Bonin F; Peyrade F; Trümper L; Diehl V; Engert A; Kube D; Re D
Oncologist; 2013; 18(1):80-9. PubMed ID: 23299779
[TBL] [Abstract][Full Text] [Related]
17. An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.
Jahn T; Zuther M; Friedrichs B; Heuser C; Guhlke S; Abken H; Hombach AA
PLoS One; 2012; 7(9):e44482. PubMed ID: 23028547
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.
Sato T; Terai M; Tamura Y; Alexeev V; Mastrangelo MJ; Selvan SR
Immunol Res; 2011 Dec; 51(2-3):170-82. PubMed ID: 22139852
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.
Mahipal A; Terai M; Berd D; Chervoneva I; Patel K; Mastrangelo MJ; Sato T
Cancer Immunol Immunother; 2011 Jul; 60(7):1039-45. PubMed ID: 21519827
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin disease and the role of the immune system.
Kennedy-Nasser AA; Hanley P; Bollard CM
Pediatr Hematol Oncol; 2011 Apr; 28(3):176-86. PubMed ID: 21381869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
